0.0050
-0.0050
(-50.00%)
At close: January 24 at 12:00:46 PM EST
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Geoffrey Lee | Chief Executive Officer | 62.77k | -- | -- |
| Mr. Christopher R. Cooper | Chief Financial Officer | 31.6k | -- | 1971 |
| Mr. Marek Jasinski | COO & Director | 72k | -- | 1977 |
| Mr. Thomas Jusdanis | Corporate Secretary & Independent Director | 55.53k | -- | 1958 |
NAVCO Pharmaceuticals Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
Description
NAVCO Pharmaceuticals Inc. researches, develops, manufactures, and commercializes nanotechnology products and materials. It offers aerosol spray, hand cream and sanitizer, and colloidal silver products. The company also provides COVID PCR testing, PPE, and diagnostic PCR testing, as well as textile and food solutions. Its products are used in medical, personal care products, textile, chemical, and additive industries. The company is headquartered in Burlington, Canada.
Corporate Governance
NAVCO Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available